3T1A
Crystal Structure of HIV-1 Reverse Transcriptase (K103N mutant) in Complex with Inhibitor M05
Summary for 3T1A
| Entry DOI | 10.2210/pdb3t1a/pdb |
| Related | 3T19 3TAM |
| Descriptor | Reverse Transcriptase, 1-(2,5-dichloro-3-{[5-chloro-1-(2H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-benzotriazol-4-yl]oxy}phenyl)methanamine (3 entities in total) |
| Functional Keywords | hiv-1 reverse transcriptase, non-nucleoside inhibition, nucleotidyltranferase, hiv-1, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | HIV-1 M:B_HXB2R (HIV-1) |
| Cellular location | Matrix protein p17: Virion (Potential). Capsid protein p24: Virion (Potential). Nucleocapsid protein p7: Virion (Potential). Reverse transcriptase/ribonuclease H: Virion (Potential). Integrase: Virion (Potential): P04585 |
| Total number of polymer chains | 2 |
| Total formula weight | 130235.21 |
| Authors | |
| Primary citation | Gomez, R.,Jolly, S.J.,Williams, T.,Vacca, J.P.,Torrent, M.,McGaughey, G.,Lai, M.T.,Felock, P.,Munshi, V.,Distefano, D.,Flynn, J.,Miller, M.,Yan, Y.,Reid, J.,Sanchez, R.,Liang, Y.,Paton, B.,Wan, B.L.,Anthony, N. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. J.Med.Chem., 54:7920-7933, 2011 Cited by PubMed Abstract: Highly active antiretroviral therapy (HAART) significantly reduces human immunodeficiency virus (HIV) viral load and has led to a dramatic decrease in acquired immunodeficiency syndrome (AIDS) related mortality. Despite this success, there remains a critical need for new HIV therapies to address the emergence of drug resistant viral strains. Next generation NNRTIs are sought that are effective against these mutant forms of the HIV virus. The bound conformations of our lead inhibitors, MK-1107 (1) and MK-4965 (2), were divergent about the oxymethylene linker, and each of these conformations was rigidified using two isomeric cyclic constraints. The constraint derived from the bioactive conformation of 2provided novel, highly potent NNRTIs that possess broad spectrum antiviral activity and good pharmacokinetic profiles. Systematic SAR led to the identification of indazole as the optimal conformational constraint to provide MK-6186 (3) and MK-7445 (6). Despite their reduced flexibility, these compounds had potency comparable to that of the corresponding acyclic ethers in both recombinant enzyme and cell based assays against both the wild-type and the clinically relevant mutant strains. PubMed: 21985673DOI: 10.1021/jm2010173 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.4 Å) |
Structure validation
Download full validation report
